CLAIMS

[Claim 1]

Use of an IL-33 antagonist in the manufacture of a medicament for treating, preventing, or alleviating endometriosis or adenomyosis uteri, wherein the IL-33 antagonist is an anti IL-33 antibody, an anti IL-33 receptor antibody, or a soluble IL-33 receptor.

[Claim 2]

The use of claim 1, wherein the medicament alleviates the pain of endometriosis or adenomyosis uteri.

[Claim 3]

The use of claim 1 or 2, wherein the medicament inhibits the growth of ectopic endometrial tissue in endometriosis or adenomyosis uteri.

[Claim 4]

The use of any of claims 1 to 3, wherein the medicament inhibits angiogenesis in ectopic endometrial tissue of endometriosis or adenomyosis uteri.

[Claim 5]

The use of any of claims 1 to 4, wherein the medicament inhibits fibrosis or cell proliferation in ectopic endometrial tissue.

[Claim 6]

The use of any of claims 1 to 5, wherein the medicament inhibits adhesion of ectopic endometrial tissue in endometriosis to various organs.

[Claim 7]

The use of any of claims 3 to 6, wherein the ectopic endometrial tissue is one or more cysts.

[Claim 8]

The use of any of claims 1 to 7, wherein the anti IL-33 antibody or anti-IL-33 receptor antibody is a monoclonal antibody.

[Claim 9]

The use of claim 8, wherein the anti IL-33 antibody is a human monoclonal antibody.

[Claim 10]

The use of claim 9, wherein the light chain amino acid sequence and heavy chain amino acid sequence of the anti IL-33 antibody are selected from the group consisting of SEQ ID Nos. 7 and 8, SEQ ID Nos. 9 and 10, SEQ ID Nos. 11 and 12, SEQ ID Nos. 13 and 14, and SEQ ID Nos. 15 and 16.

[Claim 11]

The use of claim 9, wherein the anti IL-33 antibody is A10-1C04, A23-1A05, A25-2C02, A25-3H04 or A26-1F02.

[Claim 12]

The use of any one of claims 1 - 7, wherein the soluble IL-33 receptor comprises a part or all of the extracellular region of ST2L protein.

[Claim 13]

The use of claim 12, wherein the extracellular region of ST2L protein comprises residues 19 - 328 of SEQ ID No. 3.

[Claim 14]

The use of any one of claims 1- 7, 12 and 13, wherein the soluble IL-33 receptor comprises a constant region of immunoglobulin.

[Claim 15]

The use of any one of claims 1 – 7 and 12 – 14, wherein the soluble IL-33 receptor is sST2-Fc.